Neutropenia - Pipeline Review, H2 2016

Published: Sep, 2016 | Pages: 93 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Neutropenia - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Neutropenia - Pipeline Review, H2 2016', provides an overview of the Neutropenia pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Neutropenia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Neutropenia and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Neutropenia
- The report reviews pipeline therapeutics for Neutropenia by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Neutropenia therapeutics and enlists all their major and minor projects
- The report assesses Neutropenia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Neutropenia

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Neutropenia
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Neutropenia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Neutropenia Overview 9
Therapeutics Development 10
Pipeline Products for Neutropenia - Overview 10
Neutropenia - Therapeutics under Development by Companies 11
Neutropenia - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Unknown Stage Products 17
Neutropenia - Products under Development by Companies 18
Neutropenia - Companies Involved in Therapeutics Development 19
Apotex Inc. 19
BeyondSpring Pharmaceuticals, Inc. 20
Biogenomics Limited 21
Cellerant Therapeutics, Inc. 22
Cleveland BioLabs, Inc. 23
Coherus BioSciences, Inc. 24
Dr. Reddy's Laboratories Limited 25
Eurofarma Laboratorios S.A. 26
Ligand Pharmaceuticals, Inc. 27
NAL Pharmaceuticals Ltd. 28
Prolong Pharmaceuticals, LLC 29
Richter Gedeon Nyrt. 30
Sandoz International GmbH 31
Therapeutic Proteins International, LLC 32
Toko Pharmaceutical Industries Co., Ltd. 33
USV Pvt Ltd 34
Neutropenia - Therapeutics Assessment 35
Assessment by Monotherapy Products 35
Assessment by Target 36
Assessment by Mechanism of Action 39
Assessment by Route of Administration 42
Assessment by Molecule Type 44
Drug Profiles 46
ACN-8337 - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
CBLB-612 - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
EC-18 - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
filgrastim - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
filgrastim - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
filgrastim - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
filgrastim - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
filgrastim - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
LG-7455 - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
pegfilgrastim - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
pegfilgrastim - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
pegfilgrastim - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
pegfilgrastim - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
pegfilgrastim - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
pegfilgrastim - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
pegfilgrastim - Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
pegfilgrastim - Drug Profile 64
Product Description 64
Mechanism Of Action 64
R&D Progress 64
pegfilgrastim - Drug Profile 65
Product Description 65
Mechanism Of Action 65
R&D Progress 65
pegfilgrastim - Drug Profile 66
Product Description 66
Mechanism Of Action 66
R&D Progress 66
pegfilgrastim - Drug Profile 67
Product Description 67
Mechanism Of Action 67
R&D Progress 67
pegfilgrastim - Drug Profile 68
Product Description 68
Mechanism Of Action 68
R&D Progress 68
pegfilgrastim (recombinant) - Drug Profile 69
Product Description 69
Mechanism Of Action 69
R&D Progress 69
plinabulin - Drug Profile 70
Product Description 70
Mechanism Of Action 70
R&D Progress 70
romyelocel-L - Drug Profile 74
Product Description 74
Mechanism Of Action 74
R&D Progress 74
ST-7 - Drug Profile 77
Product Description 77
Mechanism Of Action 77
R&D Progress 77
tamibarotene - Drug Profile 78
Product Description 78
Mechanism Of Action 78
R&D Progress 78
Neutropenia - Dormant Projects 81
Neutropenia - Product Development Milestones 83
Featured News & Press Releases 83
Sep 09, 2016: Apobiologix Announces Victory Over Amgen in Biosimilar (filgrastim) Patent Case 83
Sep 09, 2016: Apobiologix Announces Victory Over Amgen in Biosimilar (pegfilgrastim) Patent Case 83
Jul 11, 2016: Coherus Announces Positive Topline Results For CHS-1701 (Pegfilgrastim Biosimilar Candidate) Pharmacokinetic And Pharmacodynamic Biosimilarity Study 84
May 26, 2016: American Society of Clinical Oncology Selects BeyondSpring Abstract on Neutropenia Mitigation with Plinabulin Use for Publication 85
Mar 31, 2016: Launch of Key Biosimilar Medicine To Help Save Healthcare Budgets 85
Feb 11, 2016: Sandoz advances its biosimilars program with EMA acceptance of regulatory submission for biosimilar pegfilgrastim 86
Feb 01, 2016: Coherus Announces CHS-1701 (Neulasta Biosimilar) Met Both Primary Endpoints in Registration-Enabling Immunogenicity Study 87
Dec 21, 2015: Coherus BioSciences Signs Strategic Manufacturing Agreement With KBI Biopharma for Commercial Supply of CHS-1701 87
Dec 08, 2015: Coherus BioSciences Reports Update to CHS-1701 Program 87
Dec 08, 2015: EMA started the evaluation of Richter's marketing authorisation application for biosimilar pegfilgrastim 88
Dec 07, 2015: Phase III Data Shows Sandoz' Proposed Biosimilar Pegfilgrastim has Similar Safety and Efficacy as the Reference Product 88
Nov 18, 2015: Regulatory submission for Sandoz' proposed biosimilar pegfilgrastim accepted by the FDA 89
Oct 01, 2015: Coherus Announces Topline Results of CHS-1701 Pharmacokinetic and Pharmacodynamic Biosimilarity Study 90
Mar 17, 2015: Coherus Finalizes CHS-1701 BLA Enabling Clinical Program and Initiates Pivotal Pharmacokinetic and Pharmacodynamic Study 91
Feb 17, 2015: Apotex Announces FDA Has Accepted For Filing its Biosimilar Application for Filgrastim (Grastofil) 91
Appendix 92
Methodology 92
Coverage 92
Secondary Research 92
Primary Research 92
Expert Panel Validation 92
Contact Us 92
Disclaimer 93

List of Tables

Number of Products under Development for Neutropenia, H2 2016 10
Number of Products under Development by Companies, H2 2016 12
Number of Products under Development by Companies, H2 2016 (Contd..1) 13
Comparative Analysis by Late Stage Development, H2 2016 14
Comparative Analysis by Clinical Stage Development, H2 2016 15
Comparative Analysis by Early Stage Development, H2 2016 16
Comparative Analysis by Unknown Stage Development, H2 2016 17
Products under Development by Companies, H2 2016 18
Neutropenia - Pipeline by Apotex Inc., H2 2016 19
Neutropenia - Pipeline by BeyondSpring Pharmaceuticals, Inc., H2 2016 20
Neutropenia - Pipeline by Biogenomics Limited, H2 2016 21
Neutropenia - Pipeline by Cellerant Therapeutics, Inc., H2 2016 22
Neutropenia - Pipeline by Cleveland BioLabs, Inc., H2 2016 23
Neutropenia - Pipeline by Coherus BioSciences, Inc., H2 2016 24
Neutropenia - Pipeline by Dr. Reddy's Laboratories Limited, H2 2016 25
Neutropenia - Pipeline by Eurofarma Laboratorios S.A., H2 2016 26
Neutropenia - Pipeline by Ligand Pharmaceuticals, Inc., H2 2016 27
Neutropenia - Pipeline by NAL Pharmaceuticals Ltd., H2 2016 28
Neutropenia - Pipeline by Prolong Pharmaceuticals, LLC, H2 2016 29
Neutropenia - Pipeline by Richter Gedeon Nyrt., H2 2016 30
Neutropenia - Pipeline by Sandoz International GmbH, H2 2016 31
Neutropenia - Pipeline by Therapeutic Proteins International, LLC, H2 2016 32
Neutropenia - Pipeline by Toko Pharmaceutical Industries Co., Ltd., H2 2016 33
Neutropenia - Pipeline by USV Pvt Ltd, H2 2016 34
Assessment by Monotherapy Products, H2 2016 35
Number of Products by Stage and Target, H2 2016 37
Number of Products by Stage and Mechanism of Action, H2 2016 40
Number of Products by Stage and Route of Administration, H2 2016 43
Number of Products by Stage and Molecule Type, H2 2016 45
Neutropenia - Dormant Projects, H2 2016 81
Neutropenia - Dormant Projects (Contd..1), H2 2016 82